• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Tao Synergies Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8/8/25 5:17:38 PM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TAOX alert in real time by email
    false 0001571934 0001571934 2025-08-06 2025-08-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): August 6, 2025

     

    TAO Synergies Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-40458   46-1585656
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    1185 Avenue of the Americas, 3rd Floor
    New York, New York 10036
    (Address of principal executive offices and zip code)

     

    Registrant’s telephone number, including area code: (973) 242-0005

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading
    Symbol(s)
      Name of each exchange on which
    registered
    Common Stock, $0.0001 par value per share   TAOX   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company. x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

      

    Item 5.02.  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    (e) At the Special Meeting (as defined below) of TAO Synergies Inc. (the “Company”), stockholders approved an amendment and restatement of the Company’s 2020 Equity Incentive Plan (as amended and restated, the “Amended and Restated Equity Incentive Plan”) to increase the number of shares of common stock (“Common Stock”) reserved for issuance thereunder by 2,000,000 shares to 2,675,000 shares.

     

    The foregoing description of the Amended and Restated Equity Incentive Plan does not purport to be complete and is qualified in its entirety by reference to the full text of the Amended and Restated Equity Incentive Plan, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K (the “Current Report”) and incorporated herein by reference.

     

    Item 5.07. Submission of Matters to a Vote of Security Holders.

     

    On August 6, 2025, the Company held a Special Meeting of Stockholders (the “Special Meeting”). At the Special Meeting, the holders of 567,847 shares of the Company’s Common Stock, or approximately 35.23% of our outstanding shares of Common Stock, were represented in person or by proxy and, therefore, a quorum was present. At the Special Meeting, the Company’s stockholders considered three proposals, which are described briefly below and in more detail in the Proxy Statement. The final voting results for each proposal are set forth below.

     

    Proposal 1 - Approval of the Issuance of Common Stock Underlying Shares of Convertible Preferred Stock and Warrants

     

    The Company’s stockholders voted to authorize, for purposes of complying with Nasdaq Listing Rules 5635(c) and 5635(d), as applicable, the issuance of shares of Common Stock underlying shares of convertible preferred stock and warrants issued by the Company pursuant to the terms of (a) that certain Securities Purchase Agreement, dated June 9, 2025, by and among the Company and the investors named therein, (b) that certain Consulting Agreement, dated June 8, 2025, by and among the Company and the parties therein and (c) that certain engagement letter by and among the Company and GP Nurmenkari Inc. as placement agent, in an amount equal to or in excess of 20% of the Company’s Common Stock outstanding before the issuance of such convertible preferred stock and warrants (including upon the operation of anti-dilution provisions contained in such convertible preferred stock and warrants), by the following votes:

     

    Shares Voted For   Shares Voted Against   Abstentions
    500,450   66,872   525

      

    Proposal 2 – Approval of Amendment to Equity Incentive Plan

     

    The Company’s stockholders voted to approve a proposed amendment to the Synaptogenix, Inc. 2020 Equity Incentive Plan to, among other things, (a) increase the number of shares available for the grant of awards by 2,000,000 shares and (b) change the name of the Plan to “TAO Synergies Inc. 2020 Equity Incentive Plan”, by the following votes:

     

    Shares Voted For   Shares Voted Against   Abstentions
    492,781   73,988   1,078

     

    Proposal 3 - Approval of Adjournment

     

    The Company’s stockholders voted to approve the adjournment of the special meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there were insufficient votes to adopt either of Proposal #1 or Proposal #2 or to establish a quorum, by the following votes:

     

    Shares Voted For   Shares Voted Against   Abstentions
    523,728   42,865   1,254

     

     

     

     

      

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    The following exhibits are filed as part of this report:

     

    Exhibit Number   Description
    10.1   Amended and Restated TAO Synergies Inc. 2020 Equity Incentive Plan
    104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

     

     

     

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      TAO SYNERGIES INC.

     

    Date: August 8, 2025 By: /s/ Robert Weinstein
      Name: Robert Weinstein
      Title: Chief Financial Officer

     

     

     

     

    Get the next $TAOX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TAOX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TAOX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TAO Synergies Accelerates Decentralized AI Treasury Strategy with 42,111 Bittensor (TAO) Tokens Acquired and Earned Through Staking to Date

    Largest publicly traded TAO pure-play treasury company TAO treasury strategy anchored at intersection of decentralized AI and cryptocurrencies NEW YORK, Aug. 6, 2025 /PRNewswire/ -- TAO Synergies Inc. (NASDAQ:TAOX) (the "Company"), a digital asset treasury company focused on Bittensor (TAO), the premier crypto token for decentralized artificial intelligence (DeAI), today announced that, as of August 5th, 2025, it has accumulated 42,111 Bittensor (TAO) tokens to date as part of its differentiated digital asset treasury strategy. "Our TAO-focused crypto strategy is anchored at the intersection of decentralized AI and blockchain," stated TAO Synergies' Executive Chairman Joshua Silverman. "In

    8/6/25 9:15:00 AM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TAO Synergies Acquires $10 Million of Bittensor (TAO) to Become Largest Publicly Traded Pure Play TAO Holder

    29,899 TAO tokens purchased to date Stakes tokens in decentralized AI network for yield generation NEW YORK, July 17, 2025 /PRNewswire/ -- TAO Synergies Inc. (NASDAQ:TAOX) (the "Company"), a digital asset treasury company focused on Bittensor (TAO), the premier crypto token for decentralized artificial intelligence (AI), today announced that as of July 17, 2025, it has acquired 29,899 TAO tokens for a total purchase price of $10.0 million, at an average price of approximately $334 per token. The purchases of TAO are in accordance with the Company's digital asset treasury strategy directed toward TAO, the native token for Bittensor, a decentralized AI network that incentivizes the development

    7/17/25 9:15:00 AM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TAOX
    SEC Filings

    View All

    SEC Form S-8 filed by Tao Synergies Inc.

    S-8 - TAO Synergies Inc. (0001571934) (Filer)

    8/14/25 4:51:57 PM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Tao Synergies Inc.

    S-3 - TAO Synergies Inc. (0001571934) (Filer)

    8/14/25 4:50:01 PM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Tao Synergies Inc.

    10-Q - TAO Synergies Inc. (0001571934) (Filer)

    8/14/25 4:19:26 PM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TAOX
    Financials

    Live finance-specific insights

    View All

    TAO Synergies Acquires $10 Million of Bittensor (TAO) to Become Largest Publicly Traded Pure Play TAO Holder

    29,899 TAO tokens purchased to date Stakes tokens in decentralized AI network for yield generation NEW YORK, July 17, 2025 /PRNewswire/ -- TAO Synergies Inc. (NASDAQ:TAOX) (the "Company"), a digital asset treasury company focused on Bittensor (TAO), the premier crypto token for decentralized artificial intelligence (AI), today announced that as of July 17, 2025, it has acquired 29,899 TAO tokens for a total purchase price of $10.0 million, at an average price of approximately $334 per token. The purchases of TAO are in accordance with the Company's digital asset treasury strategy directed toward TAO, the native token for Bittensor, a decentralized AI network that incentivizes the development

    7/17/25 9:15:00 AM ET
    $TAOX
    Biotechnology: Pharmaceutical Preparations
    Health Care